Behavioral dysfunctions (BPSD) represent the most important problem in Alzheimer's dementia (AD) management. We assessed the serum levels of two myokines in AD patients, preliminary investigating, as secondary aim, their role as potential biomarkers for agitation/aggression (AA) and aberrant motor behavior (AMB): irisin, since it is able to modify the motor pattern, and BDNF, since it was transcribed following irisin stimulation. Forty AD patients were recruited and characterized according to the expressed neuropsychiatric syndrome. Myokines were measured by ELISA. Irisin serum levels were slightly elevated in AA+ patients (+ 10.0%; p < 0.05) and correlated with the duration of AA (r = 0.74, p < 0.03). BDNF failed to show such differences. We propose that these selected myokines are not useful as surrogate markers for agitation in AD, but might represent interesting secondary outcomes when testing drugs for those BPSD implying elevated motor activity

Conti, E., Grana, D., Stefanoni, G., Corsini, A., Botta, M., Magni, P., et al. (2019). Irisin and BDNF serum levels and behavioral disturbances in Alzheimer's disease. NEUROLOGICAL SCIENCES, 40(6), 1145-1150 [10.1007/s10072-019-03781-y].

Irisin and BDNF serum levels and behavioral disturbances in Alzheimer's disease

Conti, Elisa
Primo
;
Grana, Denise
Secondo
;
Stefanoni, Giovanni;Aliprandi, Angelo;Appollonio, Ildebrando;Ferrarese, Carlo
Penultimo
;
Tremolizzo, Lucio
Ultimo
2019

Abstract

Behavioral dysfunctions (BPSD) represent the most important problem in Alzheimer's dementia (AD) management. We assessed the serum levels of two myokines in AD patients, preliminary investigating, as secondary aim, their role as potential biomarkers for agitation/aggression (AA) and aberrant motor behavior (AMB): irisin, since it is able to modify the motor pattern, and BDNF, since it was transcribed following irisin stimulation. Forty AD patients were recruited and characterized according to the expressed neuropsychiatric syndrome. Myokines were measured by ELISA. Irisin serum levels were slightly elevated in AA+ patients (+ 10.0%; p < 0.05) and correlated with the duration of AA (r = 0.74, p < 0.03). BDNF failed to show such differences. We propose that these selected myokines are not useful as surrogate markers for agitation in AD, but might represent interesting secondary outcomes when testing drugs for those BPSD implying elevated motor activity
Articolo in rivista - Articolo scientifico
Alzheimer’s disease; BDNF; BPSD; Irisin; Myokines
English
27-feb-2019
2019
40
6
1145
1150
none
Conti, E., Grana, D., Stefanoni, G., Corsini, A., Botta, M., Magni, P., et al. (2019). Irisin and BDNF serum levels and behavioral disturbances in Alzheimer's disease. NEUROLOGICAL SCIENCES, 40(6), 1145-1150 [10.1007/s10072-019-03781-y].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/221066
Citazioni
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
Social impact